Zentiva Pharma GmbH secures contract for Pharmaceutical products - Conclusion of a non-exclusive discount agreement according to Section 130a Paragraph 8 SGB V for the active ingredient dimethyl fumarate (excl. 240mg, N3), ATC L04AX07 fdZ 011025-300927 (plus extension 1x12 months)

Posted On: 2026-08-07

Germany, Aug. 7 -- Germany based Zentiva Pharma GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products - Conclusion of a non-exclusive discount agreement according to Section 130a Paragraph 8 SGB V for the active ingredient dimethyl fumarate (excl. 240mg, N3), ATC L04AX07 fdZ 011025-300927 (plus extension 1x12 months) . The value of the contract is not disclosed .

Published by HT Digital Content Services with permission from Pivotal Sources....

इस लेख के रीप्रिंट को खरीदने या इस प्रकाशन का पूरा फ़ीड प्राप्त करने के लिए, कृपया हमे संपर्क करें.

विशेष

Category

Source

Publication

Location

Zentiva Pharma GmbH secures contract for Pharmaceutical products - Conclusion of a non-exclusive discount agreement according to Section 130a Paragraph 8 SGB V for the active ingredient dimethyl fumarate (excl. 240mg, N3), ATC L04AX07 fdZ 011025-300927 (plus extension 1x12 months)